Abstract
Opioid analgesics are the most frequently prescribed medications for the treatment of moderate or severe pain; however, their use is constrained by unwanted side effects. One therapeutic approach used to improve the side effect profile of opioids is the administration of a second drug in an opioid-containing mixture. Preclinical studies designed to predict the therapeutic potential of novel opioid-containing drug combinations are currently underway, and must rely on quantitative methods to assess their interactive effects. In this manuscript, an overview of isobolographic analysis is presented along with recent advances in isobolographic theory pertaining to drugs that differ in efficacy and to the statistical analysis of dose-addition. Next, studies using these analyses to assess the interactive effects of opioids and novel adjunct drugs, including selective COX-2 inhibitors, α2-adrenergic receptor agonists, δopioids, glutamate receptor antagonists and cannabinoid receptor agonists, are reviewed. Finally, comments on the future assessment of drug combinations for the treatment of pain-related disorders are made.
Keywords: Drug combination, isobologram, dose-addition, pain, opioid, analgesia, NSAID, ALpha2ARs, NMDAR
CNS & Neurological Disorders - Drug Targets
Title: Preclinical Assessment of Drug Combinations for the Treatment of Pain: Isobolographic and Dose-Addition Analysis of the Opioidergic System
Volume: 10 Issue: 5
Author(s): Bradford D. Fischer
Affiliation:
Keywords: Drug combination, isobologram, dose-addition, pain, opioid, analgesia, NSAID, ALpha2ARs, NMDAR
Abstract: Opioid analgesics are the most frequently prescribed medications for the treatment of moderate or severe pain; however, their use is constrained by unwanted side effects. One therapeutic approach used to improve the side effect profile of opioids is the administration of a second drug in an opioid-containing mixture. Preclinical studies designed to predict the therapeutic potential of novel opioid-containing drug combinations are currently underway, and must rely on quantitative methods to assess their interactive effects. In this manuscript, an overview of isobolographic analysis is presented along with recent advances in isobolographic theory pertaining to drugs that differ in efficacy and to the statistical analysis of dose-addition. Next, studies using these analyses to assess the interactive effects of opioids and novel adjunct drugs, including selective COX-2 inhibitors, α2-adrenergic receptor agonists, δopioids, glutamate receptor antagonists and cannabinoid receptor agonists, are reviewed. Finally, comments on the future assessment of drug combinations for the treatment of pain-related disorders are made.
Export Options
About this article
Cite this article as:
D. Fischer Bradford, Preclinical Assessment of Drug Combinations for the Treatment of Pain: Isobolographic and Dose-Addition Analysis of the Opioidergic System, CNS & Neurological Disorders - Drug Targets 2011; 10 (5) . https://dx.doi.org/10.2174/187152711796235050
DOI https://dx.doi.org/10.2174/187152711796235050 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Dynamics Simulations of Metalloproteinases Types 2 and 3 Reveal Differences in the Dynamic Behavior of the S1 Binding Pocket
Current Pharmaceutical Design Visible Light Assisted Hantzsch Reaction: Synthesis of Polycyclic Dihydropyridines
Letters in Organic Chemistry Editorial (Hot Topic: Bioactive Components of Plant Products Including Polyphenols Exert Neuroprotective Effects and Benefit Neural Function)
Central Nervous System Agents in Medicinal Chemistry Incorporation of Targeted Agents in the Management of Patients with Advanced Gastric Cancer
Current Medicinal Chemistry Antipsychotic Medication Adherence and Satisfaction Among Palestinian People with Schizophrenia
Current Clinical Pharmacology Administration of a Synbiotic to Free-Living Elderly and Evaluation of Serum Cytokines. A Pilot Study
Current Pharmaceutical Design The Genetic Components of Alcohol and Nicotine Co-Addiction: From Genes to Behavior
Current Drug Abuse Reviews Gender Differences in P-Glycoprotein Expression and Function: Effects on Drug Disposition and Outcome
Current Drug Metabolism Molecular Dynamics and Regulation of Butyrylcholinesterase Cholinergic Activity by RNA Binding Proteins
CNS & Neurological Disorders - Drug Targets The High pH and pH-Shift Refolding Technology
Current Pharmaceutical Biotechnology Conference Report:
CNS & Neurological Disorders - Drug Targets Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design Off-Label Use of Sunitinib in Patients with Advanced, Epithelial Thyroid Cancer: A Retrospective Analysis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Early-phase 18F-AV-45 PET Imaging can Detect Crossed Cerebellar Diaschisis Following Carotid Artery Stenosis and Cerebral Hypoperfusion
Current Neurovascular Research Meet Our Editorial Board Member
Current Neuropharmacology Pharmacoperones: A New Therapeutic Approach for Diseases Caused By Misfolded G Protein-Coupled Receptors
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Differences in Saccadic Eye Movements in Subjects at High and Low Risk for Panic Disorder
Current Pharmaceutical Design Blue-Enriched Lighting for Older People Living in Care Homes: Effect on Activity, Actigraphic Sleep, Mood and Alertness
Current Alzheimer Research Meal Replacement Beverage Twice a Day in Overweight and Obese Adults (MDRC2012-001)
Current Nutrition & Food Science ACKNOWLEDGEMENTS TO THE REVIEWERS
CNS & Neurological Disorders - Drug Targets